西罗莫司药物涂层球囊联合临时支架对比常规药物洗脱支架治疗新发冠状动脉病变的随机开放标签非劣效试验
该多中心随机开放标签非劣效试验纳入3323例新发冠状动脉病变患者,比较基于西罗莫司药物涂层球囊(SEB)联合临时支架策略与常规药物洗脱支架(DES)植入策略。主要终点为1年靶血管失败,SEB策略组发生率为5.3%,DES组为4.4%,风险差0.91%(95%CI -0.55%至2.38%),单侧P=0.02满足非劣效界值2.44%。但符合方案集分析未能确认非劣效性,且SEB组临床驱动的靶血管血运重建更常见(3.3% vs 2.1%)。
要点
- SEB联合临时支架策略在主要意向性分析人群中1年靶血管失败非劣效于常规DES。
- SEB组临时支架 bailout 比例为20.7%,临床驱动靶血管血运重建发生率高于DES组。
- 符合方案集敏感性分析未确认非劣效性,需关注后续5年随访结果。
核心结论
- 在意向性治疗分析人群中,SEB联合临时DES策略1年靶血管失败非劣效于常规DES植入。
- 符合方案集敏感性分析未能确认非劣效性,且SEB组临床驱动靶血管血运重建更频繁。
研究设计与样本
- 多中心、开放标签、随机、非劣效试验,纳入冠状动脉直径2至5 mm的新发病变患者。
- 共3323例受试者按1:1随机,在经皮冠状动脉介入治疗前分组,主要分析基于意向性治疗原则。
- 主要终点为靶血管失败,包括心源性死亡、靶血管相关心肌梗死和临床驱动靶血管血运重建。
- 非劣效界值为合并事件率的50%,单侧显著性水平0.025,1年时检验。
主要发现
- SEB策略组1661例中343例(20.7%)进行了 bailout 支架植入。
- 365天内靶血管失败在SEB组发生88例(5.3%),系统DES组73例(4.4%),风险差0.91%(95%CI -0.55%至2.38%),单侧P=0.02满足2.44%非劣效界值。
- 临床驱动靶血管血运重建在SEB组更常见(3.3% vs 2.1%;风险差1.22%[95%CI 0.11%-2.33%])。
- 安全性事件包括病变内血栓形成发生率低且两组相似。
- 符合方案集分析(3194例,96%)未确认非劣效性(95%CI上限2.63,P=0.04),但效应大小和方向与意向性分析相似。
关键数值与推荐
- 非劣效界值为合并事件率的50%,实际使用2.44%作为界值。
- 主要终点1年靶血管失败风险差0.91%(95%CI -0.55%至2.38%),单侧P=0.02。
- 临床驱动靶血管血运重建风险差1.22%(95%CI 0.11%-2.33%)。
临床怎么用
- 对于新发冠状动脉病变,SEB联合临时支架策略可作为常规DES植入的替代选择,但需权衡靶血管血运重建风险。
- 临时支架 bailout 比例约五分之一,临床决策需结合病变特征和患者意愿。
局限性
- 符合方案集敏感性分析未确认非劣效性,结果稳健性受限。
- 开放标签设计可能影响临床驱动血运重建的判定。
- 1年随访时间较短,长期非劣效性或优效性尚待5年结果验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Implantation of drug eluting stents (DESs) is currently the default approach for percutaneous coronary interventions, but long-term adverse events still exist. An approach with minimal stenting deserves to be assessed in a randomized trial. We studied a novel sirolimus-eluting balloon (SEB) that elutes sirolimus over a 90-day period using a biodegradable polymer microreservoir technology. METHODS: In a multicenter, open-label, randomized trial, we compared an SEB-based strategy with provisional DES with one of systematic DES for de novo lesions in coronary arteries between 2 and 5 mm in diameter. Subjects were randomized 1:1 before percutaneous coronary intervention. The primary end point was target vessel failure, a composite of cardiac death, target vessel-related myocardial infarction, and clinically driven target vessel revascularization. It was tested for noninferiority at 1 year with the use of an absolute margin equal to 50% of the combined event rate at a significance level of 0.025. The primary analysis population included all randomized subjects with completed or attempted percutaneous revascularization, analyzed according to the intention-to-treat principle. A sensitivity analysis was performed on the per-protocol population. RESULTS: Between August 27, 2021, and July 29, 2024, 3323 participants were randomized and treated in 62 sites. Among 1661 participants in the SEB strategy group, bailout stenting was performed in 343 (20.7%). Target vessel failure occurred over 365 days in 88 (5.3%) and 73 (4.4%) participants in the SEB and the systematic DES strategy groups, respectively (risk difference, 0.91% [95% CI -0.55% to 2.38%]; 1-sided P=0.02 for noninferiority with a 2.44% noninferiority margin). Clinically driven target vessel revascularization occurred more frequently in the SEB strategy group (3.3% versus 2.1%; risk difference, 1.22% [95% CI, 0.11%-2.33%). Safety events, including lesion thrombosis, were low and similar in both groups. Although the results of the per-protocol population (3194 participants, 96%) did not confirm noninferiority (upper boundary of the 95% CI, 2.63; P=0.04), they were similar to the intention-to-treat results in both magnitude and direction. CONCLUSIONS: At 1 year, in the primary intention-to-treat analysis population, a strategy of percutaneous coronary intervention with SEB and provisional DES was noninferior to the systematic use of DES for the primary end point of target vessel failure. The per-protocol population sensitivity analysis did not confirm noninferiority. Clinically driven target vessel revascularization occurred more frequently in the SEB strategy group. At 5 years, target vessel failure will be tested again for noninferiority and for superiority if noninferiority is achieved. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04859985.
引用
- Spaulding C, Krackhardt F, Bogaerts K, et al. Sirolimus-Eluting Balloon With Provisional Stenting Versus Systematic Drug-Eluting Stent Implantation to Treat De Novo Coronary Lesions: A Randomized, Open-Label, Noninferiority Trial. Circulation. 2026. PMID: 42290366. doi:10.1161/CIRCULATIONAHA.126.079033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。